News Bluebird bio details plans to file three blockbusters Biotech looks to take on Novartis, Gilead, and Juno in CAR-T
News Celgene in talks to buy CAR-T partner Juno Celgene is understood to be in talks to buy CAR-T specialists Juno Therapeutics, in a deal which could be worth around $7 billion.
News Cellectis gets FDA go-ahead to restart fatal CAR-T trial Regulator agrees to restart phase 1 trial of UCART 123
News Kite in CAR-T pole position as rolling submission begins Kite to start filing data for KTE-C19 with US regulator.
Digital Chaos & opportunity: Dr Adam Brown unpacks US health policy Dive into our video interview with Dr Adam Brown as he unpacks the chaos and opportunity shaping US health policy.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
